Answers are grounded in this paper and cite their sources.
This article focuses on the GDNF family of neurotrophic factors as a potential new class of therapeutics for neuropathic pain, with a particular emphasis on the ligands, artemin and GDNF. In vivo activity of the ligands, expression of ligands and receptors after peripheral nerve injury, and modulation of nerve injury-induced changes by the ligands are reviewed in detail. Structural considerations, particularly with regard to implications for binding interactions and biological activity are discussed.
No takes yet. Share an insight, caveat, or question.
Sah et al. (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: